AAV 介导的糖脂生物合成缺陷基因治疗。
AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies.
机构信息
Horae Gene Therapy Center, University of Massachusetts Medical School, Worcester, MA, USA; Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA, USA.
Department of Neurology, University of Massachusetts Medical School, Worcester, MA, USA; Li Weibo Institute for Rare Diseases Research, University of Massachusetts Medical School, Worcester, MA, USA.
出版信息
Trends Mol Med. 2021 Jun;27(6):520-523. doi: 10.1016/j.molmed.2021.02.004. Epub 2021 Mar 10.
Abstract
De novo glycosphingolipid (GSL) biosynthesis defects cause severe neurological diseases, including hereditary sensory and autonomic neuropathy type 1A (HSAN1A), GM3 synthase deficiency, and hereditary spastic paraplegia type 26 (HSPG26), each lacking effective treatment. Recombinant adeno-associated virus (AAV)-mediated gene therapy has emerged as a powerful treatment for monogenic diseases and might be particularly suitable for these neurological conditions.
摘要
从头糖脂（GSL）生物合成缺陷可引起严重的神经疾病，包括遗传性感觉和自主神经病 1A 型（HSAN1A）、GM3 合酶缺乏症和遗传性痉挛性截瘫 26 型（HSPG26），这些疾病目前均缺乏有效治疗方法。重组腺相关病毒（AAV）介导的基因治疗已成为单基因疾病的一种有效治疗方法，可能特别适用于这些神经疾病。
相似文献
1
AAV-Mediated Gene Therapy for Glycosphingolipid Biosynthesis Deficiencies.AAV 介导的糖脂生物合成缺陷基因治疗。
Trends Mol Med. 2021 Jun;27(6):520-523. doi: 10.1016/j.molmed.2021.02.004. Epub 2021 Mar 10.
2
AAV gene therapy for hereditary spastic paraplegia type 50: a phase 1 trial in a single patient.50 型遗传性痉挛性截瘫的 AAV 基因治疗：单例患者的 1 期试验。
Nat Med. 2024 Jul;30(7):1882-1887. doi: 10.1038/s41591-024-03078-4. Epub 2024 Jun 28.
3
Intrathecal AAV9/AP4M1 gene therapy for hereditary spastic paraplegia 50 shows safety and efficacy in preclinical studies.鞘内注射 AAV9/AP4M1 基因治疗遗传性痉挛性截瘫 50 型在临床前研究中显示出安全性和疗效。
J Clin Invest. 2023 May 15;133(10):e164575. doi: 10.1172/JCI164575.
4
Adeno-Associated Virus Vector for Central Nervous System Gene Therapy.用于中枢神经系统基因治疗的腺相关病毒载体
Trends Mol Med. 2021 Jun;27(6):524-537. doi: 10.1016/j.molmed.2021.03.010. Epub 2021 Apr 21.
5
Adeno-associated virus-based vectors in gene therapy.基因治疗中基于腺相关病毒的载体
J Biomed Sci. 2000 Jul-Aug;7(4):279-91. doi: 10.1007/BF02253246.
6
Next Generation of Adeno-Associated Virus Vectors for Gene Therapy for Human Liver Diseases.用于人类肝脏疾病基因治疗的新一代腺相关病毒载体。
Gastroenterol Clin North Am. 2019 Jun;48(2):319-330. doi: 10.1016/j.gtc.2019.02.005. Epub 2019 Apr 1.
7
Gene therapy for epilepsy.癫痫的基因治疗
Metab Brain Dis. 2010 Sep;25(3):363-6. doi: 10.1007/s11011-010-9209-7. Epub 2010 Sep 23.
8
Adeno-associated viral vectors for gene therapy of inherited retinal degenerations.用于遗传性视网膜变性基因治疗的腺相关病毒载体。
Methods Mol Biol. 2013;935:351-69. doi: 10.1007/978-1-62703-080-9_25.
9
Viral vector-mediated gene therapy for opioid use disorders.病毒载体介导的基因治疗阿片类药物使用障碍。
Exp Neurol. 2021 Jul;341:113710. doi: 10.1016/j.expneurol.2021.113710. Epub 2021 Mar 26.
10
Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.腺相关病毒（AAV）作为基因治疗的载体
BioDrugs. 2017 Aug;31(4):317-334. doi: 10.1007/s40259-017-0234-5.
引用本文的文献
1
Synthetic GM1 improves motor and memory dysfunctions in mice with monoallelic or biallelic disruption of GM3 synthase.人工合成 GM1 可改善单等位基因突变或双等位基因突变 GM3 合酶的小鼠的运动和记忆功能障碍。
FEBS Open Bio. 2023 Sep;13(9):1651-1657. doi: 10.1002/2211-5463.13669. Epub 2023 Jul 13.
2
Rescue of GM3 synthase deficiency by spatially controlled, rAAV-mediated ST3GAL5 delivery.通过空间控制、rAAV 介导的 ST3GAL5 递送来拯救 GM3 合酶缺乏症。
JCI Insight. 2023 May 8;8(9):e168688. doi: 10.1172/jci.insight.168688.
3
Upregulation of CCNB2 and Its Perspective Mechanisms in Cerebral Ischemic Stroke and All Subtypes of Lung Cancer: A Comprehensive Study.CCNB2在脑缺血性中风和所有肺癌亚型中的上调及其潜在机制：一项综合研究
Front Integr Neurosci. 2022 Jul 19;16:854540. doi: 10.3389/fnint.2022.854540. eCollection 2022.
4
Functional validation of novel variants in B4GALNT1 associated with early-onset complex hereditary spastic paraplegia with impaired ganglioside synthesis.B4GALNT1 中与神经节苷脂合成受损的早发性复杂遗传性痉挛性截瘫相关的新型变异体的功能验证。
Am J Med Genet A. 2022 Sep;188(9):2590-2598. doi: 10.1002/ajmg.a.62880. Epub 2022 Jul 1.
5
Genetic pain loss disorders.遗传性疼痛缺失障碍。
Nat Rev Dis Primers. 2022 Jun 16;8(1):41. doi: 10.1038/s41572-022-00365-7.
本文引用的文献
1
Effective and Accurate Gene Silencing by a Recombinant AAV-Compatible MicroRNA Scaffold.通过重组 AAV 兼容的 microRNA 支架实现有效的、准确的基因沉默。
Mol Ther. 2020 Feb 5;28(2):422-430. doi: 10.1016/j.ymthe.2019.11.018. Epub 2019 Nov 27.
2
Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality.治疗性 AAV 基因向神经系统的转移：临床现实。
Neuron. 2019 Mar 6;101(5):839-862. doi: 10.1016/j.neuron.2019.02.017.
3
Adeno-associated virus vector as a platform for gene therapy delivery.腺相关病毒载体作为基因治疗传递的平台。
Nat Rev Drug Discov. 2019 May;18(5):358-378. doi: 10.1038/s41573-019-0012-9.
4
Recessive GM3 synthase deficiency: Natural history, biochemistry, and therapeutic frontier.GM3 合酶缺乏症的隐性遗传：自然病史、生物化学和治疗前沿。
Mol Genet Metab. 2019 Apr;126(4):475-488. doi: 10.1016/j.ymgme.2019.01.013. Epub 2019 Jan 21.
5
Ganglioside GM3 as a gatekeeper of obesity-associated insulin resistance: Evidence and mechanisms.神经节苷脂GM3作为肥胖相关胰岛素抵抗的守门人：证据与机制
FEBS Lett. 2015 Oct 24;589(21):3221-7. doi: 10.1016/j.febslet.2015.09.018. Epub 2015 Oct 8.
6
Gangliosides: glycosphingolipids essential for normal neural development and function.神经节苷脂：对于正常的神经发育和功能至关重要的糖鞘脂。
Trends Biochem Sci. 2015 Jul;40(7):397-406. doi: 10.1016/j.tibs.2015.03.007. Epub 2015 May 1.
7
Natural history and biomarkers in hereditary sensory neuropathy type 1.遗传性感觉神经病1型的自然病史和生物标志物
Muscle Nerve. 2015 Apr;51(4):489-95. doi: 10.1002/mus.24336. Epub 2015 Feb 11.
8
Alteration of ganglioside biosynthesis responsible for complex hereditary spastic paraplegia.神经节苷脂生物合成的改变导致复杂遗传性痉挛性截瘫。
Am J Hum Genet. 2013 Jul 11;93(1):118-23. doi: 10.1016/j.ajhg.2013.05.006. Epub 2013 Jun 6.
9
MicroRNA-regulated, systemically delivered rAAV9: a step closer to CNS-restricted transgene expression.microRNA 调控的、系统性递送的 rAAV9：更接近中枢神经系统限制型转基因表达的一步。
Mol Ther. 2011 Mar;19(3):526-35. doi: 10.1038/mt.2010.279. Epub 2010 Dec 21.
10
Overexpression of the wild-type SPT1 subunit lowers desoxysphingolipid levels and rescues the phenotype of HSAN1.野生型SPT1亚基的过表达降低了脱氧鞘脂水平并挽救了遗传性感觉神经病1型（HSAN1）的表型。
J Neurosci. 2009 Nov 18;29(46):14646-51. doi: 10.1523/JNEUROSCI.2536-09.2009.
Zotero 插件